MAPRE1 and breast neoplasm: In the present study, we provide several lines of evidence demonstrating a novel function of EB1 in regulating cancer cell sensitivity to the microtubule-targeting agent paclitaxel: a) EB1 expression in breast tumor tissues correlates with the pathological response of tumors to paclitaxel treatment; b) EB1 expression correlates with paclitaxel sensitivity in breast cancer cell lines; and c) knockdown of EB1 expression decreases paclitaxel sensitivity in breast cancer cells and overexpression of EB1 has the opposite effect.